• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In

The Future: Pharmacogenetics in Primary Care

Home / Pharmacogenetics / The Future: Pharmacogenetics in Primary Care

Genelex Blog

The Future: Pharmacogenetics in Primary Care

primary carePrimary care physicians are in a prime position to advance the continued implementation of pharmacogenetic testing to improve patient care, according to a review article in the journal Primary Care Reports.

The article, which appeared in the October issue of Primary Care Reports, makes the case that primary care physicians are ideally positioned to advise patients in a manner that will make pharmacogenetic, or drug-sensitivity, testing more clinically useful. The authors write that not only are the vast majority of prescriptions written in the primary care setting, but that an estimated 60 percent of adverse drug events (ADEs) take place in the primary care setting. ADEs, defined as any injury resulting from drug use, contributed to an estimated 13.5 million patient visits between 2005 and 2007.

The review article’s authors report that education for primary care physicians on pharmacogenetic testing is an important first step in expanding the use of this technology, citing two published surveys that found a marked lack of self-reported understanding of this testing among primary care physicians. Creating protocols to determine which patients would most benefit from pharmacogenetic testing will also be a key consideration for primary care physicians.

“Despite significant barriers and pitfalls, creating solid protocols for implementation will yield optimal results for physicians and patients as genetic information takes a more prominent place in patient care,” the review article authors conclude.

An online CME course through AHC Media focusing on this Primary Care Reports article is available and costs $33.75 for those who do not subscribe to the journal. Learn about what credits are offered through the course, read the article and take the test via the Genelex resources page here.

The article was co-authored by Genelex regional pharmacist liaison Brian Hocum, PharmD, CGP.

Genelex Resources

Affected Conditions
Affected Drugs
Info for Providers
Frequently Asked Questions
Contact Genelex
Join Our Mailing List

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.